Adiponectin and leptin in relation to insulin sensitivity

Metabolic Syndrome and Related Disorders

Volumn 2, Issue 2, 2004, Pages 114-123

  Soodini, Geetha R ^a   Hamdy, Osama ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; CYTOKINE; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIUM LESION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

EID: 9144235551     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2004.2.114     Document Type: Review

References (94)

1. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
2. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221:286-289.
3. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-10703.
4. Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin binding protein purified from plasma. J Biochem 1996;120: 803-812.
5. Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose specific gene, adiponectin. Int J Obes 2000;24:861-868.
6. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
7. Freubis J, Tsao TS, Javorschi S, et al. Proteolytic clevage product of 30kDa adipocyte-complement related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005-2010.
8. Yamauchi T, Kamen J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769.
9. Nadler ST, Stoehr JP, Schueler KL, et al. The expression of adipogenic genes is decreased in obesity and diabetes meltitus. Proc Natl Acad Sci USA 2000;97: 11371-11376.
10. Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133.
11. Kuboto N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal proliferation. J Biol Chem 2002;277:25863-25866.
12. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737.
13. Yamauchi T, Kamon J, Waki H, et al. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
14. Stefan N, Bunt JC, Salbe AD, et al. Plasma adiponectin concentration in children: relations with obesity and insulinemia. J Clin Endocrinol Metab 2002; 87:4652-4656.
15. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal weight and obese women. Eur J Endocrinol 2002;147:173-180.
16. Nishizawa H, Shimomura I, Kishida K, et al. Androgens decrease plasma adiponectin, an insulin sensitizing adipocyte derived protein. Diabetes 2002;51: 2734-2741.
17. Hotta K, Funahashi T, Arita Y, et al. Plasma concentration of a novel adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
18. Monzillo LU, Hamdy O, Horton ES, et al. Effect of life-style modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003;11:1048-1054.
19. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-3819.
20. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
21. Abbasi F, Chu JW, Mclaughlin T, et al. Obesity versus insulin resistance in modulation of plasma adiponectin concentration. Diabetes 2002;52(suppl 1):A81.
22. Stephen N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole body insulin sensitivity in humans. Diabetes 2002 51:1884-1888.
23. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-58.
24. Spanger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-28.
25. Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care 2003;26:2015-2020.
26. Lihn AS, Ostergard T, Nyholm B, et al. Adiponectin mRNA expression in subcutaneous adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2003;284: E443-E448.
27. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population Diabetes 2002;51:536-540.
28. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002;51:2306-2312.
29. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes. A candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325-2328.
30. Lin WS, Chang HM, Tai TY, et al. Effect of thiazolidinedione on gene expression in NIH3T3-L1 adipocytes. Diabetes 1999;48(suppl 1):A-217.
31. Maeda N, Takahashi M, Funahashi T, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes 2001;50:2094-2099.
32. Coombs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kDa by PPAR-gamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
33. Yu JG, Javorschi H, Henever AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
34. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.
35. Schubert UK, Kaplan RC, Rood J, et al. The serum adiponectin response to rosiglitazone in type 2 diabetes is not affected by co-administration of glyburide or metformin. Diabetes 2003; 52(suppl 1):A543.
36. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
37. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulated the growth of myelmonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-1732.
38. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-Kappa B signaling through a camp dependent pathway. Circulation 2000;102:1296-1301.
39. Kern PA, DiGregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relationship to obesity, insulin resistance and TNF alpha expression. Diabetes 2003;52(suppl 1):A329.
40. Aldahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003; Aug 3:293-298.
41. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derives bioactive substances. Ann N Y Acad Sci 1999;892:146-154.
42. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Circulation 1999; 100:2473-2476.
43. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063.
44. Okamoto Y, Arita Y, Nishida M, et al. An adipocyte derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47-50.
45. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277:37487-37491.
46. Mantzoros CS. The role of leptin in human obesity and disease. Ann Intern Med 1999;130:671-680.
47. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
48. Zhang F, Babinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387:206-209.
49. Madej T, Boguski MS, Bryant SH. Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett 1995;373:13-18.
50. Elmquist JK, Ahima RS, Maratos-Flier E, et al. Leptin activates neurons in the ventrobasal hypothalamus and brainstem. Endocrinology 1997;138:839-842.
51. Elmquist JK, Ahima RS, Elias CS, et al. Leptin activates distinct projections from the dorsomedial and ventromedial hypothalamic nuclei. Proc Natl Acad Sci USA 1998;95:741-748.
52. Lonnqvist F, Arner P, Nordfors L, et al. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995;1:950-993.
53. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334: 292-295.
54. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant Leptin for weight loss in obese and lean adults: a randomized control dose escalation trial. JAMA 1999;282:1568-1575.
55. Caro JF, Kolazynski JW, Nyce MR, et al. Decreased cerebrospinal fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 1996; 348:159-161.
56. Montague CT, Prins JB, Sanders L, et al. Depot and sex specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes 1997; 46:342-347.
57. Hickey MS, Houmard JA, Considine RV, et al. Gender-dependent effects of exercise training on serum leptin levels in humans. Am J Physiol 1997;272:E562-E566.
58. Saad MF, Damani S, Gingerich RL, et al. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997;82:579-584.
59. Ostlund RE Jr, Wang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 1996;81:3909-3913.
60. Shimizu H, Shimomura Y, Nakanihi Y, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 1997;154:285-292.
61. Okumura T, Taniguchi A, Nagasaka S, et al. Relationship of regional adiposity to serum leptin level in nonobese Japanese type 2 diabetic male patients. Diabetes Metab 2003;29:15-18.
62. Kolaczynski JW, Considine RV, Ohannesian J, et al. Responses of leptin to short-term and refeeding in humans. Diabetes 1996;45:1511-1515.
63. Kolaczynski JW, Ohannesian JP, Considine RV, et al. Response of leptin to short term and prolonged overfeeding in humans. J Clin Endocrinol Metab 1996;81: 4162-4165.
64. Jenkins AB, Markovic TP, Fleury A, et al. Carbohydrate intake and short term regulation of leptin in humans. Diabetologia 1997;40:348-351.
65. Mantzoros CS, Prasad AS, Beck F, et al. Zinc may regulate serum leptin concentrations in humans. J Am Coll Nutr 1998;17:270-275.
66. Saladin R, Dvos P, Guerro-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995;377:527-529.
67. Rentsch J, Chiesi M. Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett 1996;379:55-59.
68. MacDougald OA, Hwang CS, Fan H, et al. Regulated expression of the obese gene product in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1995;92:9034-9037.
69. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and Chronic effects of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 1996; 45:699-701.
70. Boden G, Chen X, Kolacynski JPM. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997;100:1107-1113.
71. Segal KR, Landt M, Klien S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-991.
72. Zimmet PZ, Collins VR, de Courten MP, et al. Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean of Mauritius. Int J Obes Relat Metab Disord 1998;22:171-177.
73. Nyholm B, Fisker S, Lund S, et al. Increased circulating leptin concentration in insulin-resistant first-degree relatives of patients with non-insulin dependent diabetes mellitus: relationship to body composition and insulin sensitivity but not to family history of NIDDM. Eur J Endocrinol 1997;136: 173-179.
74. Johannsson G, Karlsson C, Lonn L, et al. Serum leptin concentration and insulin sensitivity in men with abdominal obesity. Obes Res 1998;6:416-421.
75. Tatti P, Masselli L, Buonanno A, et al. Leptin levels in diabetic and nondiabetic subjects. Endocrine 2001;15: 305-308.
76. Wauters M, Considine RV, Yudkin JS, et al. Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Horm Metab Res 2003;35:92-96.
77. Fischer S, Hanefeld M, Haffner SM, et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002;39:105-110.
78. Peterson KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-1350.
79. Barbier M, Cherbut C, Aube AC, et al. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 1998; 43:783-790.
80. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12:57-65.
81. Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 1999;194:6-11.
82. Bullo M, Garcai-Lorda P, Megias I, et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2002;11:525-531.
83. Maruna P, Gurulich R, Frasko R, et al. Serum leptin levels in septic men correlate well with C-reactive protein and TNF-alpha but not with BMI. Physiol Res 2001;50:589-594.
84. Macchi M, Pieroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNF alpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004;28: 993-997.
85. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 2003;26:2883-2889.
86. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999;48:426-429.
87. Corsonello A, Malara A, De Domenico D, et al. Identifying pathways involved in leptin-dependent aggregation of human platelets. Int J Obes Relat Metab Disord 2004;28:979-984.
88. Corsonello A, Perticone F, Malara A, et al. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord 2003;27:566-573.
89. Watanabe S, Takeuchi Y, Fukumoto S, et al. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 2003;21:166-171.
90. Willi SM, Kennedy A, Wallace P, et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 2002;51:2895-2902.
91. Williams LB, Fawcett RL, Waechter AS, et al. Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab 2000;85:2678-2684.
92. Nolan JJ, Olefsky JM, Nyce MR, et al. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 1996;45:1276-1278.
93. Baratta R, Amato S, Patane G, et al. Adiponectin and leptin: relationship with the insulin resistance syndrome. Diabetes 2003;52:A81.
94. Park KG, Park KS, Kim MJ, et al. Relationship between surem adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 2004;63:135-142.